Genetic ablation of Fgfr isoforms in MEFs and human prostate cancer cells results in increased OCR (Liu et al., 2018), while Fgf2−/− mice exhibit increased WAT and BAT mtDNA copy number (Li et al., 2021). Here, FGF2 is linked to prostate carcinoma.